TXA vs. Amicar in Total Knee and Hip Arthroplasty
Blood Loss, Hip Arthritis, Knee Arthritis
About this trial
This is an interventional treatment trial for Blood Loss
Eligibility Criteria
Inclusion Criteria:
- Patients electing to undergo primary total hip or knee arthroplasty
Exclusion Criteria:
- History of stents
- Myocardial infarction,
- Cerebrovascular accident or stroke
- Deep venous thrombus
- Pulmonary embolus
- Late onset color blindness
- Hypercoagulable state
Sites / Locations
- Duke University Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Tranexamic Acid (TXA)
Epsilon-aminocaproic acid (Amicar)
TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team. All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization.
Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team. All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization.